This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Large Drugmakers Set to Rule the Sector in 2021
by Kinjel Shah
Large Cap Pharmaceuticals industry players maintain a cautious outlook after mixed Q3 show. COVID-19 vaccine development efforts play a crucial role in driving the industry. PFE, MRK, NVS may prove to be good additions to your portfolio.
Blueprint Medicines (BPMC) Rises 40% in Past 3 Months: Here's Why
by Zacks Equity Research
Blueprint Medicines' (BPMC) lead drug, Ayvakit, approved for PDGFRA Exon 18 mutant GIST is off to a solid start. The company's second drug, Gavreto, gets approved for two types of cancer indications.
Novartis (NVS) Gets CRL From the FDA for Cholesterol Drug
by Zacks Equity Research
Novartis (NVS) gets CRL from the FDA for its cholesterol drug, inclisiran, due to unresolved facility inspection-related conditions.
Ultragenyx (RARE), Mereo Ink Deal for Bone Disease Candidate
by Zacks Equity Research
Ultragenyx (RARE) and Mereo BioPharma ink an agreement for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta.
Pharma Stock Roundup: FDA Emergency Nod to PFE/BNTX COVID-19 Vaccine, AZN to Buy ALXN
by Kinjel Shah
FDA grants approval for emergency use of Pfizer's (PFE) COVID-19 vaccine. AstraZeneca (AZN) offers to buy Alexion.
Novartis (NVS) to Acquire Neuroscience Company for Up to $770M
by Zacks Equity Research
Novartis (NVS) to buy neuroscience company, Cadent, for up to $770 million.
Gilead's (GILD) CAR T Cell Therapy Tecartus Wins EC Nod
by Zacks Equity Research
Gilead (GILD) company, Kite, gets conditional marketing authorization for CAR T cell therapy, Tecartus.
Novartis' (NVS) Entresto Gets FDA Panel Nod for Expanded Use
by Zacks Equity Research
Novartis (NVS) gets positive review from the FDA Advisory Committee to support the use of Entresto in the treatment of patients with heart failure with preserved ejection fraction.
Novartis' (NVS) COVID-19 Study Fails to Meet Primary Endpoint
by Zacks Equity Research
Novartis' (NVS) late-stage study on ruxolitinib in COVID-19 patients did not meet its primary endpoint.
AbbVie's (ABBV) Rinvoq Gets CHMP Nod for Two New Indications
by Zacks Equity Research
AbbVie (ABBV) gets positive opinion from the Committee for Medicinal Products for Human Use, recommending approval of Rinvoq for treating active psoriatic arthritis and active ankylosing spondylitis.
Pharma Stock Roundup: FDA Panel's Nod to PFE/BNTX Coronavirus Vaccine, Other Updates
by Kinjel Shah
An FDA panel recommends granting approval for emergency use of Pfizer's (PFE) COVID-19 vaccine. Glaxo (GSK)/Sanofi (SNY) COVID-19 vaccine plan delays.
AbbVie's (ABBV) Rinvoq Meets Goal in Ulcerative Colitis Study
by Zacks Equity Research
AbbVie's (ABBV) phase III U-ACHIEVE study evaluating Rinvoq for treating patients with moderate to severe ulcerative colitis achieves the primary goal. The study also met all secondary endpoints.
Gilead's (GILD) Kite Presents Data on CAR T Cell Therapy at ASH
by Zacks Equity Research
Gilead (GILD) posts positive data on CAR T Cell Therapy Yescarta from multiple studies at ASH.
Roche's (RHHBY) Xolair Gets FDA Nod for Label Expansion
by Zacks Equity Research
Roche (RHHBY) wins FDA approval of the label expansion of Xolair along with EUA for a serology test.
Deciphera (DCPH) Ends Qinlock Second-Line GIST Study Enrollment
by Zacks Equity Research
Deciphera (DCPH) completes enrollment in the phase III study evaluating Qinlock in patients with second-line gastrointestinal stromal tumor.
Should Value Investors Consider Novartis (NVS) Stock Now?
by Zacks Equity Research
Let's see if Novartis AG (NVS) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Alnylam (ALNY) Gets FDA Nod for Oxlumo to Treat Renal Disease
by Zacks Equity Research
The FDA approves Alnylam's (ALNY) Oxlumo injection for subcutaneous use, to lower urinary oxalate levels in pediatric and adult patients with primary hyperoxaluria type 1.
Novartis (NVS) Partners With Mesoblast for ARDS Cell Therapy
by Zacks Equity Research
Novartis (NVS) enters into a license agreement with Mesoblast for remestemcel-L for the treatment of acute respiratory distress syndrome and other indications.
Alnylam (ALNY) Gets EU Nod for Oxlumo to Treat Renal Disease
by Zacks Equity Research
Alnylam (ALNY) gets European approval for Oxlumo (lumasiran) for the treatment of primary hyperoxaluria type 1 in all age groups.
Pharma Stock Roundup: PFE COVID-19 Vaccine Final Analysis, FDA Updates & More
by Kinjel Shah
Pfizer (PFE) COVID-19 vaccine candidate proves to be 95% effective in final analysis. Sanofi (SNY), Lilly (LLY), Merck (MRK) & Glaxo (GSK) provide FDA updates.
Sanofi (SNY) Pompe Disease Drug Gets FDA's Priority Tag
by Zacks Equity Research
The FDA gives priority review tag to Sanofi's (SNY) avalglucosidase alfa for Pompe disease and Fast Track status to rilzabrutinib for immune thrombocytopenia.
Biogen Alzheimer's Drug Aducanumab Gets Rejected by FDA Panel
by Zacks Equity Research
If Biogen's (BIIB) aducanumab is approved by the FDA going forward, it will become the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.
Alnylam's (ALNY) Q3 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Alnylam (ALNY) reports a wider-than-expected loss, while sales beat estimates in the third quarter of 2020.
Regeneron's (REGN) Q3 Earnings & Sales Surpass Estimates
by Zacks Equity Research
Regeneron (REGN) beats on both earnings and sales in the third quarter of 2020 on strong performances by Eylea and Dupixent. Shares rise in pre-market trading.
Incyte (INCY) Q3 Earnings & Sales Miss, Jakafi Demand Strong
by Zacks Equity Research
Incyte (INCY) misses earnings and sales expectations in the third quarter. However, the company's lead drug, Jakafi, reports encouraging growth.